Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
 - EconoTimes)
NEW YORK, March 04, 2016 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against PTC Therapeutics (“PTC” or the “Company”) (Nasdaq:PTC) in the United States District Court for the District of New Jersey on behalf of a class consisting of all persons or entities who purchased PTC securities between May 6, 2014 and February 23, 2016, inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that during the Class Period, Defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects and that as a result of defendants’ alleged false and misleading statements, the Company’s stock traded at artificially inflated prices during the Class Period. According to the Complaint, on February 23, 2016, PTC announced that it received a Refuse to File letter from the United States Food and Drug Administration (“FDA”) regarding PTC’s New Drug Application (“NDA”) for Translarna™ (ataluren), an oral, first-in-class, protein restoration therapy for the treatment of nonsense mutation Duchenne muscular dystrophy (“nmDMD”). The FDA stated in the Refuse to File letter that the application was not sufficiently complete to permit a substantive review.
On this news, shares of PTC plummeted over 61%, closing at $10.84 per share on February 23, 2016, on heavy trading volume.
If you wish to serve as lead plaintiff, you must move the Court no later than May 2, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.
